Gemini Therapeutics (GMTX) Competitors $54.35 -0.11 (-0.20%) As of 02/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends GMTX vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELANShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Gemini Therapeutics (NASDAQ:GMTX) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Which has higher valuation and earnings, GMTX or QGEN? Qiagen has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-54.35Qiagen$1.98B4.38$83.59M$0.36108.65 Does the MarketBeat Community believe in GMTX or QGEN? Qiagen received 230 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. However, 63.33% of users gave Gemini Therapeutics an outperform vote while only 60.29% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformGemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% QiagenOutperform Votes24960.29% Underperform Votes16439.71% Which has more risk & volatility, GMTX or QGEN? Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Do analysts prefer GMTX or QGEN? Qiagen has a consensus target price of $47.71, suggesting a potential upside of 22.27%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Is GMTX or QGEN more profitable? Qiagen has a net margin of 4.23% compared to Gemini Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.92% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Qiagen 4.23%13.92%8.40% Does the media favor GMTX or QGEN? In the previous week, Qiagen had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Qiagen and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 beat Qiagen's score of -0.37 indicating that Gemini Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of GMTX or QGEN? 75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryQiagen beats Gemini Therapeutics on 13 of the 17 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.35B$7.07B$5.80B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-54.356.0226.3218.88Price / SalesN/A316.05452.0876.91Price / CashN/A67.8344.0437.47Price / Book18.816.757.644.66Net Income-$71.87M$138.11M$3.18B$245.69M7 Day Performance0.46%-1.85%-1.66%-2.22%1 Month Performance-6.69%-1.39%0.41%-1.95%1 Year Performance-18.17%-2.92%17.47%14.12% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$54.35-0.2%N/A-17.4%$2.35BN/A-54.3530News CoverageQGENQiagen4.4279 of 5 stars$39.85-0.5%$48.78+22.4%-7.3%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.1758 of 5 stars$144.08+1.1%$193.43+34.3%-1.4%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.7251 of 5 stars$10.56+1.1%$18.08+71.2%-7.1%$7.69B$122.59M1.87860Insider TradeRVMDRevolution Medicines4.5108 of 5 stars$40.67-1.6%$66.25+62.9%+44.9%$6.84B$11.58M-11.33250LEGNLegend Biotech2.5939 of 5 stars$36.42+0.1%$79.50+118.3%-35.2%$6.65B$285.14M-38.341,800Positive NewsBBIOBridgeBio Pharma4.7193 of 5 stars$34.90+10.6%$49.08+40.6%+2.4%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5264 of 5 stars$131.15-0.4%$147.13+12.2%+59.2%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.9925 of 5 stars$93.94-1.3%$123.83+31.8%+3.4%$5.97B$249.38M-44.52640Earnings ReportTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.0563 of 5 stars$11.26-3.4%$16.29+44.7%-31.0%$5.57B$4.42B28.159,300Analyst Forecast Related Companies and Tools Related Companies Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Blueprint Medicines Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GMTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
